| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 28.03% | UBS | $28 → $33 | Maintains | Buy |
| 08/23/2023 | 4.75% | JP Morgan | $18.5 → $27 | Maintains | Neutral |
| 08/21/2023 | 16.39% | Citigroup | $20 → $30 | Maintains | Buy |
| 07/20/2023 | 0.87% | Credit Suisse | $15 → $26 | Upgrades | Underperform → Neutral |
| 07/10/2023 | 12.51% | Goldman Sachs | $22 → $29 | Maintains | Buy |
| 06/22/2023 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/18/2023 | -34.04% | Banco Bradesco BBI S.A | $25 → $17 | Downgrades | Outperform → Neutral |
| 05/16/2023 | -14.65% | Goldman Sachs | $20 → $22 | Maintains | Buy |
| 03/31/2023 | -18.53% | UBS | $28 → $21 | Maintains | Buy |
| 03/02/2023 | -22.41% | Goldman Sachs | $30 → $20 | Maintains | Buy |
| 02/28/2023 | -22.41% | HSBC | $26 → $20 | Maintains | Buy |
| 02/27/2023 | -26.29% | Citigroup | $24 → $19 | Maintains | Buy |
| 02/17/2023 | -41.8% | Credit Suisse | $27 → $15 | Downgrades | Neutral → Underperform |
| 01/18/2023 | 16.39% | Goldman Sachs | $35 → $30 | Maintains | Buy |
| 11/28/2022 | 35.79% | Goldman Sachs | $40 → $35 | Maintains | Buy |
| 10/13/2022 | 55.19% | Goldman Sachs | $46 → $40 | Maintains | Buy |
| 08/16/2022 | 55.19% | Goldman Sachs | $46 → $40 | Maintains | Buy |
| 08/11/2022 | -10.77% | JP Morgan | → $23 | Downgrades | Overweight → Neutral |
| 06/07/2022 | 20.27% | UBS | $37 → $31 | Upgrades | Neutral → Buy |
| 10/15/2021 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 05/25/2021 | 66.83% | Credit Suisse | $40 → $43 | Upgrades | Underperform → Neutral |
| 04/29/2021 | 78.47% | HSBC | → $46 | Initiates Coverage On | → Buy |
| 10/16/2020 | 93.99% | B of A Securities | $20 → $50 | Upgrades | Underperform → Neutral |
| 06/24/2020 | 55.19% | Credit Suisse | $22 → $40 | Downgrades | Neutral → Underperform |
| 06/01/2020 | 8.63% | JP Morgan | $33 → $28 | Downgrades | Overweight → Neutral |
| 04/27/2020 | -22.41% | B of A Securities | $43 → $20 | Downgrades | Neutral → Underperform |
| 04/03/2020 | 0.87% | Citigroup | → $26 | Upgrades | Neutral → Buy |
| 01/06/2020 | 74.59% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
| 01/06/2020 | 70.71% | JP Morgan | → $44 | Initiates Coverage On | → Neutral |
| 01/06/2020 | 55.19% | Goldman Sachs | → $40 | Initiates Coverage On | → Neutral |
What is the target price for XP (XP)?
The latest price target for XP (NASDAQ: XP) was reported by UBS on September 1, 2023. The analyst firm set a price target for $33.00 expecting XP to rise to within 12 months (a possible 28.03% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for XP (XP)?
The latest analyst rating for XP (NASDAQ: XP) was provided by UBS, and XP maintained their buy rating.
When is the next analyst rating going to be posted or updated for XP (XP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of XP, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for XP was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
Is the Analyst Rating XP (XP) correct?
While ratings are subjective and will change, the latest XP (XP) rating was a maintained with a price target of $28.00 to $33.00. The current price XP (XP) is trading at is $25.78, which is out of the analyst's predicted range.